The BioTraceIO software reportedly facilitates visualization of liver tumor ablation procedures based on real-time ultrasound imaging and provides superior post-op estimates of ablation zone volume in comparison to computed tomography.
The Food and Drug Administration (FDA) has granted De Novo clearance for the ultrasound-based BioTraceIO, a software that offers enhanced post-op estimates of tissue response after liver tumor ablation procedures.
Employing a unique computational algorithm, BioTraceIO (Techsomed) assesses real-time ultrasound images and utilizes technical parameters of the ablation device’s manufacturer to provide clinicians with registration of the reference ablation zone.
Techsomed said the software subsequently provides an immediate post-op visual estimate of liver tumor ablation on tissue response. A multicenter study found that BioTraceIO offered superior ablation zone estimates of tissue response at 24 hours in comparison to post-op contrast-enhanced computed tomography (CECT), according to Techsomed.
"Imaging plays a crucial role in tumor ablation. While ultrasound serves as a cost-efficient and patient-friendly option for real-time visualization, there is a potential for enhanced visualization and continuous monitoring of the ablation tissue response,” noted Nami Azar, M.D., a professor of radiology in the Department of Radiology within the School of Medicine at Case Western Reserve University in Cleveland. “BioTraceIO opens new possibilities in utilizing ultrasound for liver ablation procedures. I am excited to witness its impact in action and the advancements it brings to our field.”
Leading Breast Radiologists Discuss the USPSTF Breast Cancer Screening Recommendations
May 17th 2024In recognition of National Women’s Health Week, Dana Bonaminio, MD, Amy Patel, MD, and Stacy Smith-Foley, MD, shared their thoughts and perspectives on the recently updated breast cancer screening recommendations from the United States Preventive Services Task Force (USPSTF).
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Multicenter CT Study Shows Benefits of Emerging Diagnostic Model for Clear Cell Renal Cell Carcinoma
May 15th 2024Combining clinical and CT features, adjunctive use of a classification and regression tree (CART) diagnostic model demonstrated AUCs for detecting clear cell renal cell carcinoma (ccRCC) that were 15 to 22 percent higher than unassisted radiologist assessments.
CT Study: AI Algorithm Comparable to Radiologists in Differentiating Small Renal Masses
May 14th 2024An emerging deep learning algorithm had a lower AUC and sensitivity than urological radiologists for differentiating between small renal masses on computed tomography (CT) scans but had a 21 percent higher sensitivity rate than non-urological radiologists, according to new research.